Ulcerative Colitis (UC) Market in China 2023
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum. It is characterized by inflammation, ulcers, and bleeding in the colon and rectum, which can lead to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The exact cause of ulcerative colitis is unknown, but it is thought to be related to an abnormal immune response in which the body's immune system attacks the cells of the digestive tract. The condition may also be influenced by genetic and environmental factors. There are several treatment options available to manage the symptoms and complications of ulcerative colitis, including medications to reduce inflammation and suppress the immune system, dietary changes, and surgery to remove the affected portion of the colon or rectum in severe cases. According to the latest estimates, the ulcerative colitis in China market size is expected to increase from USD 857.8 million in 2022 to USD 2,061.0 million by 2029, garnering a CAGR of 13.09% over the evaluated period.
This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and product. The China market data on ulcerative colitis can be segmented by type: mild ulcerative colitis, moderate to severe ulcerative colitis. Ulcerative colitis market is further segmented by product: infliximab, mesalazine, sulfasalazine (SSZ), others.
As of 2022, the major players in the China ulcerative colitis market were Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Ulcerative Colitis Market
Identify segments/areas to invest in over the forecast period in the China Ulcerative Colitis Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and product. The China market data on ulcerative colitis can be segmented by type: mild ulcerative colitis, moderate to severe ulcerative colitis. Ulcerative colitis market is further segmented by product: infliximab, mesalazine, sulfasalazine (SSZ), others.
As of 2022, the major players in the China ulcerative colitis market were Losan Pharma GmbH, Ferring Holding SA, Guangdong Qiangji Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Shanghai Sine Tianping Pharmaceutical Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Get a detailed picture of the China Ulcerative Colitis Market
Identify segments/areas to invest in over the forecast period in the China Ulcerative Colitis Market
Understand the competitive environment, the market’s leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Ulcerative colitis market overview
Part 4. Market breakdown by type
Mild ulcerative colitis
Moderate to severe ulcerative colitis
Part 5. Market breakdown by product
Infliximab
Mesalazine
Sulfasalazine (SSZ)
Others
Part 6. Key companies
Losan Pharma GmbH
Ferring Holding SA
Guangdong Qiangji Pharmaceutical Co., Ltd.
Janssen Pharmaceuticals, Inc.
Shanghai Sine Tianping Pharmaceutical Co., Ltd.
Part 7. Methodology
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Ulcerative colitis market overview
Part 4. Market breakdown by type
Mild ulcerative colitis
Moderate to severe ulcerative colitis
Part 5. Market breakdown by product
Infliximab
Mesalazine
Sulfasalazine (SSZ)
Others
Part 6. Key companies
Losan Pharma GmbH
Ferring Holding SA
Guangdong Qiangji Pharmaceutical Co., Ltd.
Janssen Pharmaceuticals, Inc.
Shanghai Sine Tianping Pharmaceutical Co., Ltd.
Part 7. Methodology
